BR112023004388A2 - Método para preparar um produto de hidróxido de ferro e produto de hidróxido de ferro - Google Patents

Método para preparar um produto de hidróxido de ferro e produto de hidróxido de ferro

Info

Publication number
BR112023004388A2
BR112023004388A2 BR112023004388A BR112023004388A BR112023004388A2 BR 112023004388 A2 BR112023004388 A2 BR 112023004388A2 BR 112023004388 A BR112023004388 A BR 112023004388A BR 112023004388 A BR112023004388 A BR 112023004388A BR 112023004388 A2 BR112023004388 A2 BR 112023004388A2
Authority
BR
Brazil
Prior art keywords
iron hydroxide
hydroxide product
preparing
product
base solution
Prior art date
Application number
BR112023004388A
Other languages
English (en)
Inventor
Wu Chien-Chin
Original Assignee
Lg Bionano Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202011055787.3A external-priority patent/CN112156109A/zh
Priority claimed from CN202011055789.2A external-priority patent/CN112168844A/zh
Application filed by Lg Bionano Llc filed Critical Lg Bionano Llc
Publication of BR112023004388A2 publication Critical patent/BR112023004388A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Compounds Of Iron (AREA)
  • Medicinal Preparation (AREA)

Abstract

MÉTODO PARA PREPARAR UM PRODUTO DE HIDRÓXIDO DE FERRO E PRODUTO DE HIDRÓXIDO DE FERRO. É fornecido um método para preparar um produto de hidróxido de ferro. O método inclui as etapas de: adicionar uma primeira solução de base a uma solução de um sal férrico para obter uma Mistura A que tem um valor de pH de 2,7-2,8, adicionar uma segunda solução de base à Mistura A para preparar uma suspensão de hidróxido de ferro cru que tem um valor de pH de 2,8-3,8 e adicionar uma terceira solução de base para ajustar o pH da suspensão de hidróxido de ferro cru para 5-9, seguido de purificação e concentração, obtendo, assim, uma suspensão de hidróxido de ferro polinuclear purificada que contém hidróxido de ferro polinuclear. São fornecidos também nanocomplexos férricos, por exemplo complexo de carboidrato de hidróxido de ferro, e seus métodos de preparação.
BR112023004388A 2020-09-29 2021-09-29 Método para preparar um produto de hidróxido de ferro e produto de hidróxido de ferro BR112023004388A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011055787.3A CN112156109A (zh) 2020-09-29 2020-09-29 氢氧化铁-糖络合物的制备方法及其应用
CN202011055789.2A CN112168844A (zh) 2020-09-29 2020-09-29 一种氢氧化铁碳水化合物复合物的制备方法
PCT/US2021/052571 WO2022072439A1 (en) 2020-09-29 2021-09-29 Methods of preparing iron complexes

Publications (1)

Publication Number Publication Date
BR112023004388A2 true BR112023004388A2 (pt) 2023-04-04

Family

ID=80950851

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023004388A BR112023004388A2 (pt) 2020-09-29 2021-09-29 Método para preparar um produto de hidróxido de ferro e produto de hidróxido de ferro

Country Status (9)

Country Link
US (1) US20240024357A1 (pt)
EP (1) EP4221723A1 (pt)
JP (1) JP2023552261A (pt)
KR (1) KR20230129973A (pt)
AU (1) AU2021351482A1 (pt)
BR (1) BR112023004388A2 (pt)
CA (1) CA3191492A1 (pt)
MX (1) MX2023003647A (pt)
WO (1) WO2022072439A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020229381A1 (en) 2019-02-28 2021-09-16 Renibus Therapeutics, Inc. Novel iron compositions and methods of making and using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3150081A (en) * 1962-08-14 1964-09-22 Du Pont Method of preventing precipitation of iron compounds from an aqueous solution
GB1200902A (en) * 1967-05-13 1970-08-05 Fisons Pharmaceuticals Ltd Iron-dextran complexes
DE10232069A1 (de) * 2002-07-16 2004-02-05 Sachtleben Chemie Gmbh Verfahren zur Herstellung von Eisenhydroxid, Eisenoxidhydrat oder Eisenoxid aus Filtersalzen der Dünnsäurerückgewinnung
CN100528237C (zh) * 2005-04-26 2009-08-19 重庆医药工业研究院有限责任公司 多核的氢氧化铁-糖复合物的制备方法
CN109893540A (zh) * 2017-12-07 2019-06-18 南京恒生制药有限公司 一种低重金属含量的蔗糖铁复合物溶液的制备方法及其产品

Also Published As

Publication number Publication date
US20240024357A1 (en) 2024-01-25
MX2023003647A (es) 2023-06-09
CA3191492A1 (en) 2022-04-07
WO2022072439A1 (en) 2022-04-07
JP2023552261A (ja) 2023-12-15
KR20230129973A (ko) 2023-09-11
EP4221723A1 (en) 2023-08-09
AU2021351482A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
BR112018070677A2 (pt) inibidores de mcl-1 macrocíclicos para o tratamento de câncer
BR112022012641A2 (pt) Compostos tricíclicos substituídos
BR112015016793A2 (pt) compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim
PE20212303A1 (es) Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer
BRPI0708685B8 (pt) composto de 4-oxoquinolina, seu uso e método para produção dos mesmos
BR112022002520A2 (pt) Piperidinil-metil-purina-aminas como inibidores de nsd2 e agentes anticâncer
BR112015028501B8 (pt) Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
BR112023004388A2 (pt) Método para preparar um produto de hidróxido de ferro e produto de hidróxido de ferro
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
BR112017005841A2 (pt) mistura de eteramina, processo para a produção de uma mistura de eteramina, e, uso de uma mistura de eteramina.
MX2019015371A (es) Derivados de dihidro-pirrolo-piridina.
BR112022020291A2 (pt) Inibidores de cd38
BR112023018095A2 (pt) Processos para sintetizar 2-fluoro-3-nitrotolueno, 1-(bromometil)-2-fluoro-3-nitrobenzeno e para preparar omecamtiv mecarbil ou um sal do mesmo, um hidrato do mesmo ou um hidrato de sal do mesmo
MX2016015652A (es) Removedor de punta de electrodo.
HUP0400549A2 (hu) Új imidazolszármazékok és eljárás előállításukra, és ezeket tartalmazó gyógyszerkészítmények
MX2023014784A (es) Preparacion de derivados de compuestos 1,2-diaminoheterociclicos sustituidos y su uso como agentes farmaceuticos.
Wu et al. Targeted isolation of sorbicilinoids from a deep-sea derived fungus with anti-neuroinflammatory activities
BR112022020007A2 (pt) Uso terapêutico de pleuromutilinas
CO2023000858A2 (es) Inhibidores de atr y usos de estos
GT200500214A (es) Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y análogos relacionados como inhibidores de la caseína cinasa epsilon
WO2022204344A3 (en) Enamine n-oxides: synthesis and application to hypoxia-responsive prodrugs and imaging agents
BR112022013161A2 (pt) Composições farmacêuticas tópicas compreendendo compostos de imidazo[1,2-b]piridazina
BR112018076309A8 (pt) Compostos de geminóide e seus usos
BR112023015721A2 (pt) Derivados tricíclicos úteis como inibidores de parp7
MX2022013890A (es) Sintesis y derivados de acido boronico, formas polimorficas y usos terapeuticos de los mismos.